Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

NCT05016544 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: inetetamab
DRUG: Pytotinib

Sponsor

Sun Yat-sen University